INTRODUCTION

On January 31, 2020, the US Secretary of Health and Human Services (HHS) declared a public health emergency due to coronavirus disease 2019 (COVID-19). Subsequently, the Emergency Use Authorization (EUA) for COVID-19 medical products has been in effect since March 27, 2020, allowing the US Food and Drug Administration (FDA) to authorize repurposed and newly developed medical products for temporary use prior to undergoing the full approval process. Each EUA...
requires that the FDA assess the following: that the medical product is appropriate for use as an emergency countermeasure, its potential benefits outweigh the risks of authorization, and there are no formally approved alternatives currently available. The data quality standard to obtain an EUA has been somewhat ambiguous, and has been particularly noted as a concern for diagnostics authorization.3– 5 For therapeutics, the typical requirement for FDA approval of a new therapeutic is two well-controlled, adequately powered randomized controlled trials (RCTs).6 Herein, we review the clinical data that were obtained to pursue EUA for antiviral and anti-inflammatory medications during the COVID-19 pandemic, with a focus on evidence of clinical efficacy and the resilience of the authorization decision as additional clinical studies of the drug were conducted. We also examine the consistency of such evidence as it was obtained across different therapeutic classes and between branded and generic medications.

METHODS

This review examines “Drugs and Non-Vaccine Biological Products” with EUA for COVID-19, classifying them as (1) novel or repurposed and (2) by mechanism—antiviral monoclonal antibodies, small molecule antivirals, and anti-inflammatory drugs (Figure 1). All clinical trials found were registered on ClinicalTrials.gov and searched by keywords, including “COVID-”, and drug names were extracted for review on January 4, 2022. Related publications or official press releases for data from each clinical trial were found on ClinicalTrials.gov, Medline, PubMed, and Google Scholar. Company websites were also used to find press-releases; BioRxiv and MedRXiv were used to find preprints.

RESULTS

Novel agents

Monoclonal antibodies

Imdevimab and casirivimab (REGEN-COV)

Data supporting authorization. REGEN-COV is a combination of two noncompeting monoclonal antibodies (mAbs) imdevimab and casirivimab, targeting the severe
acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) spike protein. The FDA granted EUA to imdevimab-casirivimab and expanded its use. The RECOVERY trial evaluated the efficacy of imdevimab-casirivimab in over 9000 patients hospitalized with COVID-19 and demonstrated significant reduction in mortality in those seronegative at baseline when compared with usual care (24% vs. 30%, \( p = 0.0010 \)). The EUA was expanded for subcutaneous injection when intravenous administration is impossible and for postexposure prophylaxis in patients 12 years or older at risk of severe COVID-19. The EUA was reissued seven times between February 2020 and January 2022. Based on diminished potency against Omicron, imdevimab-casirivimab’s EUA was limited to geographic areas where Omicron is not dominant. As a result, imdevimab-casirivimab is not currently authorized in any US region, so it may not be administered until further notice (Table S1.1).

**Bamlanivimab and etesevimab**

*Data supporting authorization.* Bamlanivimab-etesevimab is a combination of two monoclonal antibodies binding distinct but overlapping epitopes on the SARS-CoV-2 spike protein. It was given to bamlanivimab alone in November 2020, then revoked April 2021 due to resistant COVID-19 viral variants. At the time, bamlanivimab-etesevimab was already distributed more widely than bamlanivimab alone, and the cocktail was authorized in February 2021 to treat mild-to-moderate COVID-19 and individuals with high risk for serious COVID-19. The FDA cites BLAZE-1 (NCT04427501) with 3290 participants and BLAZE-4 (NCT04634409) with 1631 participants, which reported a statistically significant drop in both COVID-19-related hospitalizations (2.1% vs. 7.0%) and deaths (0% and 1.7%) in patients treated with bamlanivimab-etesevimab versus placebo (\( p < 0.001 \); Table 1).

**Post authorization.** Data from subsequent studies were consistent with studies supporting the EUA (Table S1.2). On December 3, 2021, the FDA extended authorization under the same conditions to the treatment of all pediatric patients, including those under 12 years of age. However, on December 29, 2021, the HHS paused bamlanivimab-etesevimab allocation anywhere with greater than 80% Omicron prevalence. After the National Institutes of Health (NIH) published on the variability of Omicron prevalence, the HHS allowed all states and territories to order the cocktail. The FDA reissued the EUA late January 2022 to limit use in areas with a high prevalence of nonsusceptible variants.

**Sotrovimab**

*Data supporting authorization.* Sotrovimab is an mAb targeting a conserved epitope across SARS-CoV and SARS-CoV-2 developed with the aim of creating an antibody with a high barrier to resistance as well as activity across different corona viruses. The FDA granted sotrovimab EUA in May 2021 for treatment of mild-to-moderate adult and pediatric patients that test positive for SARS-CoV-2 and are at risk of severe COVID-19, based on COMET-ICE (NCT04545060). COMET-ICE enrolled 1057 adult patients with symptomatic COVID-19 designated as high risk for COVID-19 progression. Interim analysis indicated that sotrovimab treatment led to an 85% reduction in death or need for hospitalization for over 24 h versus placebo (\( p < 0.002 \)).

**Post authorization.** In June 2021, Vir’s final COMET-ICE results stated that sotrovimab reduced risk of hospitalization for more than 24 h or death by day 29 by 79% (\( p < 0.001 \)). Safety results were consistent with interim analyses. Notable trials in progress are COMET-PEAK and COMET-TAIL, follow-up trials to COMET-ICE, and BLAZE-4 (NCT04634409). Both evaluate intravenous versus intramuscular administration, and, to date, indicate equivalent virological response from intravenous and intramuscular injections have been observed. Sotrovimab retains potency against the Omicron variant. The NIH currently recommends the use of sotrovimab over imdevimab-casirivimab and bamlanivimab-etesevimab due to its higher efficacy (Table S1.3).

**Tixagevimab and cilgavimab (Evusheld)**

*Data supporting authorization.* Evusheld is a combination of tixagevimab and cilgavimab, two long-acting IgG1 mAbs targeting nonoverlapping epitopes of the SARS-CoV-2 spike protein. In December 2021, the FDA granted tixagevimab-cilgavimab EUA for pre-exposure prophylaxis of COVID-19 in adults and children 12 years of age or older with no known recent exposure nor current infection...
| Type of drug                  | Intervention (sponsor) | Trials (ID)                          | Study description                                                                 | Study population                                                                                     | Primary outcome measures                                                                 | Key findings                                                                                     | References |
|------------------------------|------------------------|--------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------|
| Antiviral monoclonal antibody| Imdevimab-casirivimab   | COV-206710 (NCT04425629)            | Sponsored by Regeneron: double-blinded, placebo-controlled, randomized phase I–III clinical trial with reported results for 799 total patients (at the time of EUA in November 2020) | Three cohorts. Over 18 at randomization, less than 18 at randomization, pregnant at randomization: outpatients with symptomatic COVID-19 that maintain O2 saturation ≥93% on room air | Proportion of patients with AEs, infusion-related and hypersensitivity reactions; change in viral load; proportion of patients with COVID-related hospitalization or death; concentration of antibodies in serum over time | Larger reduction in viral load through day 7 than those receiving placebo (p = 0.0003). Reduced virus-related medical visits by 57% through day 29 (p = 0.024), with effects more pronounced among patients with risk factors for severe COVID-19 | 8.9.1.04   |
|                              |                        | BLAZE-1 (NCT04427501)               | Sponsored by Eli Lilly and Company: Double-blinded, placebo-controlled, randomized phase II/III clinical trial with 3290 participants | Over 18 at randomization, less than 18 at randomization, pregnant at randomization: outpatients with mild to moderate cases of COVID-19 treated with bamlanivimab monotherapy | Percent of participants who experience COVID-related hospitalization, ED visit, or death; percent of participants with viral load greater than prespecified threshold through day 7. percent of participants who experience serious adverse effect(s) by any cause; time until symptoms are resolved | No significant difference in viral load with 3 doses of bamlanivimab monotherapy compared with placebo | 105-107    |
|                              |                        | BLAZE-4 (NCT04634409)               | Sponsored by Eli Lilly and Company: Double-blinded, placebo-controlled, randomized phase II clinical trial with 1631 participants | 18 years and older: patients with mild to moderate COVID-19 treated with bamlanivimab-etesevimab dual therapy | Percent of participants with viral load (>5.27; cycle threshold value <27.5) at day 7. percent of patients experiencing COVID-19 related hospitalization or death, percent of participants demonstrating symptom resolution/improvement | Statistically significant drop in COVID-19-related hospitalizations and deaths compared with placebo (p <0.001) | 17,18      |
| Sotrovimab                   |                        | COMET-ICE (NCT04545060)             | Sponsored by Vir Biotechnology, Inc.: Multicenter, double-blind, phase III trial, with 583 patients (at time of interim analyses) | 18 years and older: high-risk (defined as at least one underlying risk factor or older age) patients with a positive reverse-transcriptase–PCR or antigen SARS-CoV-2 test result and onset of symptoms within the prior 5 days | Proportion of patients with hospitalization for more than 24 h or death, due to any cause, through day 29 | Statistically significant drop in risk of COVID-19 progression, as defined as hospitalization for >24 h or death, by 85% (p = 0.002) | 19,21      |
| Tixagevimab-cilgavimab       |                        | PROVENT (NCT04625725)               | Sponsored by AstraZeneca: Double-blinded, placebo-controlled, randomized phase III clinical trial with 5197 participants | 18 years and older: unvaccinated participants that are negative for SARS-CoV-2 testing at screening and can benefit from passive immunization with antibodies | Incidence of the first case of positive SARS-CoV-2 PCR test and symptomatic illness, AES, SAEs, MAEs, and AESIs postdose of IMP | Statistically significant reduced risk of developing positive SARS-CoV-2 with symptomatic COVID-19 illness by 83% (November 2021), 77% (December 2021) compared to placebo (p <0.001) | 29,30,108,109 |
TABLE 1 (Continued)

| Type of drug | Intervention (sponsor) | Trials (ID) | Study description | Study population | Primary outcome measures | Key findings | References |
|--------------|------------------------|-------------|-------------------|------------------|--------------------------|-------------|------------|
| Small molecule antiviral | Remdesivir (Gilead Sciences) | ACTT-1 (NCT04280705) | Sponsored by the NIAID: double-blinded, randomized, placebo-controlled phase III clinical trial with 1062 participants | 18 years and older: patients hospitalized with COVID-19 infection and at least one of the following: radiographic infiltrates, SpO2 < 94%, requiring supplemental oxygen, or requiring mechanical ventilation | Time to recovery through day 29 (either hospitalized and not requiring supplemental oxygen or not hospitalized) | Patients in the remdesivir group had a shorter time to recovery with a median 10 days as compared to the placebo group with a median 15 days (risk ratio: p < 0.0001), and fewer SAEs due to respiratory failure. The investigators stated that after adjustment for baseline imbalances in treatment group characteristics, no significant difference in efficacy was detected between a 5- and 10-day dose. | 36,81 |
| Small molecule antiviral | Remdesivir (Gilead Sciences) | (NCT04292899) | Sponsored by Gilead Sciences: Non-blinded, randomized (not stratified) phase III clinical trial with 397 participants | Age limit was amended to 12 years and older on March 15, 2020 after enrollment started on March 6, 2020 with initial limit of 18 years and older: patients with COVID-19 that are hospitalized, SpO2 < 94% or requiring supplemental oxygen, and radiographic evidence of pulmonary infiltrates | Clinical status at day 14 on a 7-point ordinal scale ranging from 1- death to 7- not hospitalized | | 37 |
| Small molecule antiviral | Remdesivir (Gilead Sciences) | N/A | Sponsored by Pfizer: Double-blinded, placebo-controlled, randomized Phase 2/3 clinical trial with 2246 participants | N/A | N/A | N/A | 88,110 |
| Small molecule antiviral | CQ/HCQ | None | EPIC-HR (NCT04960202) | N/A | N/A | N/A | Statistically significant reduction of risk of hospitalization or death by 89% compared to placebo within 3 days and 88% within 5 days of symptom onset; decreased viral load by 10-fold | |
| Small molecule antiviral | Nirmatrelvir plus ritonavir (Pfizer) | N/A | Sponsored by Pfizer: Double-blinded, placebo-controlled, randomized Phase I/II/III clinical trial with 1433 participants | 18 years and older: patients with at least one characteristic/underlying medical condition associated with increased risk of severe COVID-19 and confirmed SARS-CoV-2 infection/ symptoms within 5 days prior to randomization | Proportion of participants with COVID-19 related hospitalization or death from any cause through day 28 based on treatment initiated within 3 days of first symptoms | N/A | 51,52,111 |
| Small molecule antiviral | Molnupiravir (Merck and Ridgeback Biotherapeutics) | MOVe-OUT (NCT04575597) | Sponsored by Merck Sharpe and Dohme Corp.: Double-blinded, placebo-controlled, randomized phase I/II/III clinical trial with 1433 participants | 18 years and older; patients with mild or moderate COVID-19 and at least 1 characteristic/underlying medical condition associated with increased risk of severe COVID-19 | Percentage of participants who are hospitalized and/or die by day 29 based on treatment initiated within 3 days of first symptoms, percentage of participants with AEs, percentage of patients who discontinue study participation due to AEs | Statistically significant decrease in hospitalization by 48% compared to placebo in interim analysis (p = 0.001), 30% decrease in hospitalization compared to placebo in full data set due to decrease in hospitalization rate of placebo arm | |
| Type of drug | Intervention (sponsor) | Trials (ID) | Study description | Study population | Primary outcome measures | Key findings | References |
|--------------|------------------------|-------------|-------------------|------------------|-------------------------|-------------|------------|
| Anti-inflammatory | Baricitinib (Eli Lilly and Incyte Corporation) | ACTT-2 (NCT04401579) | Sponsored by NIAID: Double-blinded, placebo-controlled, randomized phase III clinical trial of 1033 participants | 18 years and older: patients admitted to the hospital with symptoms suggestive of COVID-19 and laboratory confirmed SARS-CoV-2; particularly those requiring supplemental oxygen or ECMO | Time to recovery through day 29 (not hospitalized or not requiring supplemental oxygen/ongoing care) | Baricitinib with remdesivir is superior to remdesivir alone, associated with fewer SAEs, those on baricitinib had a median recovery time of 7 days whereas those on just remdesivir had 8 days (rate ratio for recovery: \( p = 0.03 \)) | 65,66,112 |
| | | | | | | | |
| | COV-BARRIER (NCT04421027) | Sponsored by Eli Lilly: Double-blinded, placebo-controlled, randomized phase III clinical trial with 1585 participants | 18 years and older: patients hospitalized with COVID-19 and requiring supplemental oxygen at randomization, have indicators of progression | Percentage of participants who die or require noninvasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO) through day 28 | Statistically significant decrease in death by any cause compared to placebo (\( p = 0.0018 \)), no significant difference in progression to supplemental oxygen and invasive mechanical ventilation | 66,67,113,114 |
| Tocilizumab (Hoffman-La Roche) | RECOVERY (NCT04381936) | Sponsored by the University of Oxford: Open-label, randomized phase II/III clinical trial with 4116 participants in the tocilizumab arm | 18 years and older: patients with hypoxia (oxygen saturation <92% on room air or requiring supplemental oxygen), systemic inflammation, and no clear evidence of active infection other than SARS-CoV-2 | All-cause mortality, duration of hospital stay, composite end point of death or need for either mechanical ventilation or ECMO | All-cause mortality within 28 days of randomization was improved compared to placebo (\( p = 0.0028 \)). Treated patients were also more likely to be discharged from the hospital in 28 days | 71,81 |
| | COVACTA (NCT04320615) | Sponsored by Hoffmann-La Roche: Double-blinded, placebo-controlled, randomized phase III clinical trial with 452 participants | 18 years and older: patients hospitalized with COVID-19 pneumonia confirmed per WHO criteria and evidenced by chest X-ray or CT scan | Clinical status (assessed using 7-category ordinal scale at day 28), incidence of ICU stays by day 28 (week 4) | No benefit in 28-day mortality rate compared to placebo (\( p = 0.94 \)) | 115,116 |
| | EMPACTA (NCT04372186) | Sponsored by Genentech: Double-blinded, placebo-controlled, randomized phase III clinical trial with 377 participants | 18 years and older: patients hospitalized with COVID-19 pneumonia confirmed by a positive PCR of any specimen and radiographic imaging | Proportion of participants who died or required mechanical ventilation by day 28, time to “ready for discharge” (via body temp, respiratory rate, and oxygen saturation). | Did not impact day-to-day quality of life but did reduce likelihood of severe disease progression (leading to death or mechanical ventilation) | 117,118 |
| | REMDACTA (NCT04409262) | Sponsored by Hoffmann-La Roche: Double-blinded, placebo-controlled, randomized phase III clinical trial with 649 participants | 12 years and older: patients hospitalized with COVID-19 pneumonia confirmed by a positive PCR of any specimen and evidenced by chest X-ray or CT scan | Time from randomization to hospital discharge, “ready for discharge,” first occurrence of mechanical ventilation or death up to day 28 | Not yet available | 119 |

Abbreviations: AE, adverse event; AESI, adverse event of special interest; COVID-19, coronavirus disease 2019; CQ, chloroquine; CT, computed tomography; ECMO, extracorporeal membrane oxygenation; ED, emergency department; EUA, Emergency Use Authorization; HCQ, hydroxychloroquine; ICU, intensive care unit; IMP, investigational medicinal product; MAAE, medically attended adverse event; NIAID, National Institute of Allergy and Infectious Diseases; PCR, polymerase chain reaction; SAE, serious adverse event; SARS-CoV-2, severe acute respiratory syndrome-coronavirus 2; WHO, World Health Organization.
with COVID-19. Use is limited to moderately/severely immunocompromised individuals or those with a history of severe adverse reactions supporting inappropriate response to the COVID-19 vaccination. Tixagevimab-cilgavimab EUA letter cites PROVENT (NCT04625725), a trial of 5197 unvaccinated adult participants which demonstrated in two reports that tixagevimab-cilgavimab reduced the risk of developing symptomatic COVID-19 by 83% and 77% compared to placebo (p < 0.001\textsuperscript{29,30}; Table 1).

Post authorization. Due to tixagevimab-cilgavimab’s more recent authorization, subsequent data are limited. Several trials are in progress and focus on treatment and postexposure prophylaxis: PROVENT, TACKLE (NCT04723394), and STORMCHASER (NCT04625972). Primary analysis of TACKLE in October 2021 based on 822 patients found that tixagevimab-cilgavimab reduced the risk of developing severe COVID-19 or death by 50% in outpatients and 67% in participants who received treatment from the onset of symptoms. Ninety percent of participants were at high risk of severe COVID-19. Tixagevimab-cilgavimab has retained laboratory efficacy against Omicron, and AstraZeneca stated that it had neutralizing capacity comparable to that of patients who had recovered naturally from COVID-19, leading to no change in its EUA \textsuperscript{32,33} (Table S1.4).

Small molecule antivirals

Remdesivir

Data supporting authorization. Remdesivir, previously developed but not authorized for use against Ebola virus, is a nucleoside monophosphate prodrug that causes delayed chain termination, preventing elongation of newly synthesized viral RNA four nucleotides after remdesivir has been incorporated. Initial EUA in May 2020 authorized treatment of severe COVID-19 in hospitalized patients 12 years of age and older through intravenous administration. The EUA cited ACTT-1 (NCT04280705) and NCT04292899 (Table 1). ACTT-1, a trial of 1062 participants, found that the remdesivir group had shorter median days to recovery versus placebo (10 vs. 15, p < 0.0001) and lower mortality estimates. Gilead’s NCT04292899 trial found no significant difference in efficacy and safety between 5- versus 10-day remdesivir courses among the 397 hospitalized participants.

Post authorization. In October 2020, the FDA approved a New Drug Application (NDA) for remdesivir use in hospitalized patients with COVID-19 12 years of age and older. The EUA was revised to remove NDA-approved uses and retain EUA for use in younger hospitalized patients. Review of existing studies, including the Solidarity and DisCoVeRy trials, casts doubt on remdesivir’s efficacy in reducing mortality and hospital-stay duration. ACTT-1 was targeted for potential bias due to a greater proportion of lower-severity patients in the treatment group than placebo (Table S1.5). Gilead had initiated a phase III study of remdesivir in nonhospitalized patients at high risk for severe COVID-19, but terminated the study due to the requirement for infusion in a healthcare setting. Sequence analysis of the viral RNA polymerase suggested remdesivir would retain activity against the omicron variant. This was subsequently confirmed in a laboratory setting. In January 2022, the NDA was supplemented to approve remdesivir use in nonhospitalized patients 12 years of age and older who have mild-to-moderate COVID-19 but are at high risk for disease progression.

Nirmatrelvir plus ritonavir (Paxlovid)

Data supporting authorization. Paxlovid consists of nirmatrelvir, an SARS-CoV-2 main protease inhibitor and ritonavir, an HIV protease inhibitor and potent CYP 3A/4 inhibitor used to increase nirmatrelvir exposure. It became the first authorized oral antiviral in December 2021. Nirmatrelvir plus ritonavir is authorized for adult and pediatric patients over 12 years old with mild-to-moderate COVID-19 confirmed with positive SARS-CoV-2 test and at high risk of severe COVID-19. The EPIC-HR trial (NCT04960202) is the only clinical trial cited by the FDA and found that nirmatrelvir plus ritonavir reduced the risk of hospitalization or death by 89% versus placebo within 3 days, and 88% within 5 days of symptom onset in 2246 nonhospitalized patients with high-risk COVID-19. Nirmatrelvir plus ritonavir was also found to decrease viral load by nearly 10-fold versus placebo (Table 1).

Post authorization. Given the more recent authorization for nirmatrelvir plus ritonavir, limited post authorization data are available. EPIC- HR, EPIC-SR (NCT05011513), and NCT05047601 will examine nirmatrelvir plus ritonavir efficacy in postexposure prophylaxis and treating patients without a risk factor for severe COVID-19. EPIC-SR showed a 70% reduction in hospitalization compared to placebo for unvaccinated adults or those with at least one risk factor for severe COVID-19. Based on in vitro assessments, nirmatrelvir retains activity across SARS-CoV-2 variants, including Omicron (Table S1.6).

Molnupiravir

Data supporting authorization. Molnupiravir, is a non-chain terminating nucleoside analogue developed as an oral antiviral for treatment of COVID-19. It received
EUA in December 2021. Molnupiravir is authorized for adults with mild-to-moderate COVID-19 and at least one risk factor for severe COVID-19, as well as positive results from SAR-CoV-2 viral testing. Molnupiravir is not recommended for use during pregnancy due to the potential to cause fetal harm. The EUA was initially filed based on results from interim analysis of 762 patients from MOVE-OUT (NCT04575597) where hospitalization was decreased by 48% in molnupiravir vs placebo (p = 0.001). Largely driven by a decrease of hospitalization in the placebo arm, relative efficacy of molnupiravir treatment in the full data set presented to the EUA advisory committee was a 30% decrease versus placebo in hospitalization through day 29 (Table S1.7).

Post authorization. Although no new clinical data have been reported since the declaration of EUA, data from the MOVE-AHEAD study (NCT04939428), enrolling ~1332 participants exposed to COVID-19 is expected in 2022. Based on in vitro assessments, molnupiravir retains activity across SARS-CoV-2 variants, including Omicron (Table S1.7).

Repurposed therapeutics

Chloroquine and hydroxychloroquine

Data supporting authorization. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used to treat malaria, as well as several autoimmune diseases. In vitro screening conducted early in the pandemic demonstrated that CQ was active in cell-based models of SARS-CoV-2 infection and created interest in the value of the medication to treat COVID-19. The Trump administration began championing HCQ/CQ as treatments in early 2020, increasing public demand for investigation. In March 2020, CQ and HCQ received an EUA for treatment of COVID-19. Notably, the EUA letter did not cite supportive data from any clinical trial.

Post authorization. The EUA was immediately controversial. A broadly discussed French study, purported to provide preliminary evidence of efficacy for HCQ, was subsequently renounced by the publishing journal as not meeting their standards. Twenty-three of 325 trials of CQ/HCQ registered on ClinicalTrials.gov have reported results. Of those, just two had positive findings for the efficacy. Most trials were underpowered, terminated early, focused on safety rather than efficacy (with mixed conclusions), or concluded no statistically significant improvement of clinical outcomes from HCQ/CQ (Table S2.1). Consequently, general scientific consensus was reached and, in June 2020, the FDA revoked its COVID-19 EUA for HQC/CQ.

Anti-inflammatory drugs

Baricitinib

Data supporting authorization. Baricitinib is an oral JAK kinase inhibitor indicated for the treatment of moderately to severely active rheumatoid arthritis. It was initially authorized for COVID-19 treatment in combination with remdesivir in November 2020, and subsequently authorized for single agent use in July 2021 for treatment of hospitalized patients with COVID-19 requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The studies leading up to baricitinib’s authorization as a single agent cited in the EUA are ACTT-2 (NCT04401579), COV-BARRIER (NCT04421027), and data from NDA 207924. Baricitinib was initially evaluated in combination with remdesivir versus remdesivir alone in 1033 patients hospitalized with COVID-19 through ACTT-2, which found that baricitinib with remdesivir was superior especially among patients on high-flow oxygen or noninvasive ventilation. COV-BARRIER found a significant decrease in death by any cause by day 29 in 1585 hospitalized participants (p = 0.0018), leading to baricitinib’s authorization as a single agent (Table 1).

Post authorization. Data released since the EUA for baricitinib as a single agent have supported the findings prior to authorization. Further data from the pre-EUA COV-BARRIER study of hospitalized patients showed baricitinib in addition to standard of care (SOC) led to a 38.2% relative reduction in 28-day all-cause mortality (p = 0.0018). Similarly, studies of baricitinib in combination with SOC, remdesivir, and dexamethasone, respectively, found decreased ICU admissions (22.3% vs. 36.9%, p = 0.002) and invasive mechanical ventilation was avoided in 90% of patients (Table S2.2).

Tocilizumab

Data supporting authorization. Tocilizumab is an IL-6 receptor antagonist indicated for treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. The FDA granted EUA for tocilizumab in June 2021 for the treatment of COVID-19, for hospitalized adult and pediatric patients at least 2 years old receiving systemic corticosteroids and supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO. The FDA letter cites four clinical trials: RECOVERY (NCT04381936), COVACTA (NCT04320615), EMPACTA (NCT04372186), and
REMDACTA (NCT04409262). These trials investigated the effects of tocilizumab either alone or in combination with remdesivir in various hospitalized populations that had COVID-19 pneumonia or hypoxia and/or systemic inflammation. RECOVERY found that all-cause mortality within 28 days of randomization was 31% in the 2022 patients receiving tocilizumab and 35% in the 2094 patients receiving the placebo treatment \( (p = 0.0028^{71,72}; \text{Table 1}) \).

Post authorization. Little additional clinical data has been released after the EUA, but several trials are registered on ClinicalTrials.gov related to risk stratification with various biomarkers, specific platform trials, and expansion of treatment to other locations. In light of the Omicron variant, the European Commission extended the marketing authorization for tocilizumab to include treating COVID-19 in adults relying on systemic corticosteroids, supplemental oxygen, or other forms of mechanical ventilation.\(^{73,74}\) However, there has not been a similar authorization for tocilizumab in the United States (Table S2.3).

DISCUSSION

Several common themes emerged upon review of the data. In virtually every case, the EUA was supported by a minimum one large, RCT and the process included a commercial sponsor (Table 1). This applied to new molecules as well as branded medications with market authorization for other uses. This standard was consistent for both antiviral and anti-inflammatory therapies. When this standard was applied, the EUAs remained in place or were expanded as data from subsequent studies became available. Here, we draw a distinction between the initial EUA decision being based on inadequate information versus viral evolution curtailing efficacy over time. Indeed, were it not for their expedited access, these beneficial medicines would not have been available whereas they remained effective against the circulating strain of SARS-CoV-2.

Remdesivir presents an interesting case and potential exception. The EUA and subsequent FDA approval were supported by three RCTs, one executed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the other two conducted by Gilead. In terms of evidence supporting clinical efficacy, the NIAID study provided evidence of significant benefit. NCT04292899 was not designed to demonstrate the efficacy of remdesivir versus SOC, and, in NCT04292730, 5 days of remdesivir showed a statistically significant improvement. However, the authors noted the size of the effect was of questionable clinical relevance.\(^{37,75}\) The DisCoVeRy and Solidarity trials failed to show benefit of the use of remdesivir versus SOC. One potential explanation is the change in SOC for the latter two trials, in particular the incorporation of dexamethasone as SOC.\(^{76}\)

Notably, remdesivir was later found to be highly effective in preventing hospitalization when given in the outpatient setting, early in illness.\(^{77}\)

The lone example of an EUA issued for a therapeutic in the absence of a supporting large RCT was CQ/HCQ, and the EUA was rescinded <3 months after it was issued. The decision was roundly criticized citing the data supporting the EUA as inadequate, and the process as overly influenced by political factors.\(^{59}\) This may also serve as an example of two broader issues—the translational accuracy of non-clinical data, in particular for repurposed molecules (vide infra) and the relative difficulty in generating high quality clinical data to support the use of generic medications when a commercial sponsor is unavailable to run the clinical trials with standard rigor. The dis-coordinated response seen early in the pandemic led to the proliferation of poorly designed and executed small clinical trials, most of which were too underpowered to provide evidence of efficacy\(^{78,79}\) (Table 1).

Large, publicly supported trials with coordinated research strategies or collective databases for disparate clinical data, such as RECOVERY, ACTIV, REMAP-COVID, and Solidarity, were useful in supporting the development of branded medications, but critical to the assessment of generics. A prominent example was the demonstration of the efficacy of dexamethasone demonstrated within the RECOVERY trial (NCT04381936),\(^{80,81}\) as well as a clear negative assessment for the effectiveness of a number of other generic medications, such as HCQ, lopinavir-ritonavir, and colchicine.\(^{82-84}\)

Another benefit of rigorous clinical study was a better understanding of considerations, such as the treatment window post-symptom onset for antiviral medications, and which hospitalized patients would derive benefit from treatment with anti-inflammatory/immunosuppressant medications.\(^{85,86}\) Both remdesivir\(^{77}\) and molnupiravir\(^{87}\) were substantially more effective when given before hospitalization. Antivirals have been relatively more effective in preventing hospitalization in patients with at least one risk factor for severe COVID-19 versus a general population.\(^{88}\) Such considerations are not unique to COVID-19. Peramivir (a neuraminidase inhibitor [NAI]) was granted EUA for treatment of hospitalized patients during the H1N1 influenza outbreak in 2009 due to its i.m. or i.v. route of administration.\(^{89,90}\) Peramivir had similar or better in vitro potency to the two approved NA inhibitors and, at the time, evidence of clinical efficacy in uncomplicated influenza, but subsequent studies of peramivir efficacy in the hospital setting have been inconclusive.\(^{91}\)
Although outside the scope of this review, it should be noted that the variability and translational value of in vitro data may vary by mechanism. For direct acting antivirals, the predictive value of preclinical data is relatively high. For example, for antivirals such as protease inhibitors (HIV, hepatitis C virus, and SARS-CoV-2) or NS5A inhibitors in vitro effective concentration 90% (EC90) or higher, corrected for free fraction, has been more predictive of target exposures to obtain an antiviral effect.92–96 Treatment guidelines for the use of antibody therapies for COVID-19 are based on “current knowledge of the in vitro activities of the available products against the circulating SARS-CoV-2 variants and subvariants.”97 In vitro data were also prominently noted in the decision to authorize bebtelovimab.98 Data from repurposing screens for SARS-CoV-2, in particular for host cell targeted molecules, show more variability based on the assay used and the cell type used, making it difficult to estimate if an antiviral effect can be expected at the previously established clinical exposure (for example, maintaining exposure over the anti-viral EC90 as noted above).99–103 This would again support the need for robust clinical investigation, in particular, for generic medicines where the antiviral mechanism is incompletely understood.

CONCLUSION

The EUA provides not only a vehicle to expedite the availability of life-saving medications in the midst of a public health crisis, but also a means to assure the public that the safety and efficacy of that medication has been independently reviewed by the FDA. The authors acknowledge that our observations arise from a retrospective analysis of data for treatments for COVID-19, but many of the lessons may be applicable to future health emergencies. The vast majority of EUAs granted during the COVID-19 pandemic involved a commercial sponsor, and were supported by efficacy demonstrated in at least one large RCT. When this standard was applied, subsequent clinical study was largely supportive of the initial authorization decision. Generics offer the advantages of lower cost, broad availability, and a well-established safety profile, but lack the resources and infrastructure of a commercial sponsor to support thorough evaluation of clinical efficacy. This required the establishment of publicly funded clinical trial networks which played a critical role in COVID-19 in both validating or refuting clinical efficacy suggested from pilot clinical studies or, in some cases, from in vitro data alone. Maintaining the publically funded platform clinical trial infrastructure developed during the pandemic and funds to support the FDA review process as part of the long-term strategy for pandemic preparedness would address many of these issues. Furthermore, establishing formal guidance for the need for an RCT to obtain EUA could help reduce the ambiguity of the current standard and help shield the authorization process for undue political influence. In particular, although not required for access to generics, review and authorization could improve public trust in the medication.

ACKNOWLEDGMENTS

The authors thank Dr. Barbara Bierer, Dr. Dan Kuritzkus, and Dr. Lindsey Baden for their help in preparing this manuscript.

FUNDING INFORMATION

Funding for this review comes from Harvard Undergraduate Consulting on Business and the Environment.

CONFLICT OF INTEREST

M.N.N. has received research support from AbbVie and is a consultant for Arrakis Therapeutics and Axonis and past employee of Alkermes, Vertex Pharmaceuticals, and Cubist. All other authors declare no competing interests for this work.

ORCID

Lauren Kim https://orcid.org/0000-0001-9844-247X
Mark N. Namchuk https://orcid.org/0000-0002-5220-2275

REFERENCES

1. Lango MN. How did we get here? Short history of COVID-19 and other coronavirus-related epidemics. Head Neck. 2020;42(7):1535-1538. doi:10.1002/hed.26275
2. Emergency Use Authorization. U.S. Food and Drug Administration. Accessed September 6, 2021. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
3. Moshkovits I, Shpeshelovich D. Emergency use authorizations of COVID-19–related medical products. JAMA Intern Med. 2021;182:228-229.
4. Iwry J. FDA emergency use authorization: a brief history from 9/11 to COVID-19. Food and Drug Law Institute; 2021. Accessed January 16 2022. https://www.fdl.org/2021/09/fda-emergency-use-authorization-a-brief-history-from-9-11-to-covid-19/
5. Stroud C, Nadig L, Altevogt BM, Institute of Medicine (U.S.), National Academies Press (U.S.). Medical countermeasures dispensing: emergency use authorization and the postal model: workshop summary. National Academies Press; 2010:81. doi:10.17226/12952
6. Development & Approval Process. Drugs; 2019. Accessed March 5, 2022. https://www.fda.gov/drugs/development-approval-process-drugs
7. O’Shaughnessy JA. Emergency use authorization of REGEN-COV for COVID-19. 2022. Accessed February 28, 2022. https://www.fda.gov/media/145610/download
8. Regeneron's REGEN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients. Regeneron Pharmaceuticals Inc. 2020. Accessed September 18, 2021. https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-antibody-cocktail-reduced-viral-levels-and/

9. Regeneron's COVID-19 outpatient trial prospectively demonstrates that REGEN-COV2 antibody cocktail significantly reduced virus levels and need for further medical attention. Regeneron Pharmaceuticals Inc.; 2020. Accessed September 18, 2021. https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates/

10. Group RC, Horby PW, Maftham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021. Accessed September 20 2021. doi:10.1016/S0140-6736(22)00163-5

11. Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. bioRxiv. 2021. doi:10.1101/2021.12.07.21267432

12. Cavazzoni P. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. FDA; 2022. Accessed January 26 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron

13. Lilly. Emergency use authorization (EUA) for the treatment of COVID-19. Accessed September 18, 2021. https://www.covid19.lilly.com/baml-ete/hcp

14. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-393. doi:10.1038/s41577-021-00542-x

15. FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. FDA; 2021. Accessed September 18, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab

16. O'Shaughnessy JA. Emergency use authorization of EVUSHELD for COVID-19. 2021. Accessed January 5, 2022. https://www.fda.gov/media/154704/download

17. Levin MJ, Ustianowski A, De Wit S, et al. LB5. PROVENT: Randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized patients. 2021. Accessed December 22, 2021. Report No.: NCT04545060. https://clinicaltrials.gov/ct2/show/NCT04545060

18. GSK and vir biotechnology announce continuing progress of the COMET clinical development program for sotrovimab, Vir; 2021. Accessed September 13, 2021. https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-continuing-progress-comet/

19. Eli Lilly and Company. A randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of mono and combination therapy with monoclonal antibodies in participants with mild to moderate COVID-19 illness (BLAZE-4). 2021. Accessed January 5, 2022. Report No.: study/NCT04634409. https://clinicaltrials.gov/ct2/show/study/NCT04634409

20. Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021. https://www.nature.com/articles/d41586-021-03829-0

21. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021. doi:10.1101/2021.03.09.434607

22. NIH. The COVID-19 treatment guidelines panel's statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. NIH COVID-19 Treatment Guidelines; 2021. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/

23. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The double function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021. doi:10.1101/2021.03.09.434607

24. Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021. https://www.nature.com/articles/d41586-021-03829-0

25. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021. doi:10.1101/2021.03.09.434607

26. NIH. The COVID-19 treatment guidelines panel's statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. NIH COVID-19 Treatment Guidelines; 2021. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/

27. Ning L, Abagna HB, Jiang Q, Liu S, Huang J. Development and application of therapeutic antibodies against COVID-19. Int J Biol Sci. 2021;17(6):1486-1496. doi:10.7150/ijbs.59149

28. O'Shaughnessy JA. Emergency use authorization of EVUSHELD for COVID-19. 2021. Accessed January 5, 2022. https://www.fda.gov/media/154704/download

29. Levin MJ, Ustianowski A, De Wit S, et al. LB5. PROVENT: Phase 3 study of efficacy and safety of AZD7442 (Tixagevimab/ Cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults. Open Forum Infect Dis. 2021;8(Supplement_1):S810. doi:10.1093/ofid/ofab466.1646

30. AstraZeneca. New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention. AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html

31. AstraZeneca. AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial. AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html

32. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. 2021. doi:10.1101/2021.12.15.472828

33. AstraZeneca. Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington universities. AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron.
46. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785-6797. doi:10.1074/jbc.RA210.013679

O’Shaughnessy JA. Emergency use authorization of remdesivir for COVID-19. 2022. Accessed February 5, 2022. https://www.fda.gov/media/137564/download

47. Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. bioRxiv. 2021. doi:10.1101/2021.12.27.474275

48. Malone B, Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct Mol Biol. 2021;28(9):706-708. doi:10.1038/s41594-021-00657-8

49. O’Shaughnessy JA. Emergency use authorization of molnupiravir for COVID-19. 2021. Accessed January 5, 2022. https://www.fda.gov/media/155053/download

50. Coronavirus (COVID-19) update: FDA authorizes additional Oral antiviral for treatment of COVID-19 in certain adults. FDA; 2021. Accessed January 20, 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorization-of-oral-antiviral-treatment-covid-19-certain

51. Jayk Bernal A, Gomes da Silva MM, Musungai DB, et al. Molnupiravir for Oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021;386(6):509-520. doi:10.1056/NEJMoa2116044

52. Merck. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. MERCK; 2021. https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection/

53. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral drugs for COVID-19 – interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2015301

54. Vangeel L, De Jonghe S, Maes P, et al. Remdesivir, a direct-acting antiviral that inhibits RNA- dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785-6797. doi:10.1074/jbc.RA210.013679

55. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827-1837. doi:10.1056/NEJMoa2015301

56. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine phosphate for COVID-19 nonhospitalized patients at high risk for COVID-19 disease progression. bioRxiv. 2021. doi:10.1101/2021.12.27.474275

57. Schilling WH, White NJ. Does hydroxychloroquine still have any role in the COVID-19 pandemic? Expert Opin Pharmacother. 2021;22(10):1257-1266. doi:10.1080/14656566.2021.1898589

58. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi:10.1038/s41422-020-0282-0

59. Solander A. All the times trump has promoted hydroxychloroquine. Forbes. 2020. https://www.forbes.com/sites/andrewsole/2020/05/22/all-the-times-trump-promoted-hydroxychloroquine/?sh=4b0d10294643

60. Hinton DM. Emergency use authorization of chloroquine phosphate and hydroxychloroquine sulfate for COVID-19. 2020. Accessed August 22, 2021. https://www.fda.gov/media/136534/download

61. Schilling WH, White NJ. Does hydroxychloroquine still have any role in the COVID-19 pandemic? Expert Opin Pharmacother. 2021;22(10):1257-1266. doi:10.1080/14656566.2021.1898589

62. Pillar C. Former FDA leaders decry emergency authorization of malaria drugs for coronavirus. Science. 2020. https://www.science.org/content/article/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus

63. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949

64. Malchiels JD, Bleeker-Rovers CP, ter Heine R, et al. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin as a treatment of COVID-19: what is the evidence and what are the risks? Int J Antimicrob Agents. 2020;56(1):1-4. doi:10.1016/j.ijantimicag.2020.106056

65. Statement on IJAA paper. International society of antimicrobial chemotherapy. Accessed January 20, 2022. https://www.isac-world/news-and-publications/official-isac-statement
63. Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697-704. doi:10.1007/s40265-017-0723-3

64. O’Shaughnessy JA. Emergency use authorization of baricitinib for COVID-19. 2021. Accessed January 3, 2022. https://www.fda.gov/media/143822/download

65. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795-807. doi:10.1056/NEJMoa2031994

66. Eli Lilly and Company. Fact sheet for healthcare providers: emergency use authorization (EUA) of baricitinib. U.S. Food and Drug Administration; 2021. https://www.fda.gov/media/143823/download

67. Basu K, Hem K, Loveman C, Chiou C. Baricitinib: first global approval. 2021. Accessed January 3, 2022. https://www.fda.gov/media/150319/download

68. Tziolos N, Karofylakis E, Grigoropoulos I, et al. Real-life effectiveness and safety of Baricitinib as adjunctive to standard-of-care treatment in hospitalized patients with severe coronavirus disease 2019. Open Forum Infect Dis. 2022;9(1):1-7. doi:10.1093/ofid/ofab588

69. Izumo T, Kuse N, Awano N, et al. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. Respir Investig. 2021;59(6):799-803. doi:10.1016/j.resinv.2021.07.004

70. O’Shaughnessy JA. Emergency use authorization of tocilizumab for COVID-19. 2021. Accessed January 5, 2022. https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-results-phase-3-cov-barrier-study

71. Gupta S, Leaf DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021;397(10285):1599-1601. doi:10.1016/S0140-6736(21)00712-1

72. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-1352. doi:10.1016/S0140-6736(20)32013-4

73. Horby PW, Mañàs M, Bell JL, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-1352. doi:10.1016/S0140-6736(20)32013-4

74. Rostaing L, Malvezzi P. Steroid-based therapy and risk of infectious complications. PLoS Med. 2016;13(5):e1002025. doi:10.1371/journal.pmed.1002025

75. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi:10.1038/s41591-021-01643-9

76. Castillo Almeida NE, Kalil AC. Molympiravir: is it time to move in or move out? NEJM Evid. 2022;1(2). doi:10.1056/EVIDe2100048

77. Pfizer. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Pfizer; 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results

78. U.S. Government. Emergency use authorization of peramivir IV Fact Sheet for healthcare Providers. FDA; 2009. https://www.fda.gov/files/drugs/published/Peramivir-Fact-Sheet-for-Health-Care-Providers.pdf

79. Alame MM, Massaad E, Zaraket H. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol. 2016;7:1-14. doi:10.3389/fmicb.2016.00450

80. OWen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M (pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593. doi:10.1126/science.abc4784

81. Hickman D, Vasavanonda S, Nequist G, et al. Estimation of serum-Free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother. 2004;48(8):2911-2917. doi:10.1128/AAC.48.8.2911-2917.2004

82. Mo H, Yang C, Wang K, et al. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors: estimation of inhibitory quotient using a comparative equilibrium dialysis assay. J Viral Hepat. 2011;18(5):338-348. doi:10.1111/j.1365-2893.2010.01314.x

83. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021;9(12):1419-1426. doi:10.1016/S2213-2600(21)00435-5
95. Sofia MJ. HCV: The Journey from Discovery to a Cure: Volume II. Springer International Publishing; 2019. (Topics in Medicinal Chemistry; vol. 32). doi:10.1007/978-3-030-28400-8

96. Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating patients with coronavirus disease 2019. Clin Infect Dis. 2020;71(12):3232-3236.

doi:10.1093/cid/ciaa623

97. NIH. Anti-SARS-CoV-2 monoclonal antibodies. NIH COVID-19 Treatment Guidelines; 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/

98. O'Shaughnessy JA. Emergency Use Authorization of Bebtelovimab for COVID-19. 2022. Accessed April 8, 2022. https://www.fda.gov/media/156151/download

99. Sweiti H, Ekwunife O, Jaschinski T, Lhachimi SK. Repurposed therapeutic agents targeting the Ebola virus: a systematic review. Curr Ther Res. 2017;84:10-21. doi:10.1016/j.curtheres.2017.01.007

100. Martinez MA. What should be learned from repurposed antivirals against SARS-CoV-2? Front Microbiol. 2022;13:843587.

doi:10.3389/fmicb.2022.843587

101. Patten JJ, Keiser PT, Gysi D, et al. Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. bioRxiv. 2021.

doi:10.1101/2021.04.20.440626

102. Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113-119.

doi:10.1038/s41586-020-2577-1

103. Namchuk MN. Early returns on small molecule therapeutics for SARS-CoV-2? ACS Infect Dis. 2021;7(6):1298-1302.

doi:10.1021/acsinfectdis.0c00874

104. Regeneron Pharmaceuticals. A master protocol assessing the safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory patients with COVID-19. 2021. Report No.: NCT04425629. Accessed December 28, 2021.

https://clinicaltrials.gov/ct2/show/NCT04425629

105. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04427501

106. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as monotherapy or in combination with Etsevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325(7):632-644.

doi:10.1001/jama.2021.0202

107. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229-237.

108. Phase III double-blind, placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult. (PROVENT). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04625725

109. AstraZeneca. AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19. AstraZeneca; 2021. https://www.astrazeneca.com/content/astrazeneca/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html

110. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04960202

111. Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with COVID-19 (MK-4482-002). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04575597

112. Adaptive COVID-19 Treatment Trial 2 (ACTT-2). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT0401579

113. A study of baricitinib (LY3009104) in participants with COVID-19 (COV-BARRIER). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04421027

114. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.

doi:10.1016/S2213-2600(21)00331-3

115. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04320615

116. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503-1516.

doi:10.1056/NEJMoa2028700

117. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04372186

118. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20-30.

doi:10.1056/NEJMoa2030340

119. A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia (REMDACTA). U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04409262?term=NCT04409262&draw=2&rank=1

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Yoo S-H, Kim L, Lu M, Nagoshi K, Namchuk MN. A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics. Clin Transl Sci. 2022;15:2279-2292. doi:10.1111/cts.13384